Form 4: Emergent BioSolutions Executive Coleen Glessner Reports Changes in Beneficial Ownership

Coleen Glessner, EVP at Emergent BioSolutions, reports adjustments in her beneficial ownership due to performance stock unit payouts and tax withholdings.

Summary

• Coleen Glessner, an executive at Emergent BioSolutions, filed a Form 4 detailing changes in her beneficial ownership of company stock.
• On February 12, 2025, performance stock units (PSUs) granted under the Emergent BioSolutions Inc. Stock Incentive Plan vested, but the Compensation Committee certified a payout factor of 0.00% due to the adjusted EBITDA margin not being achieved over the three-year period from January 1, 2022, to December 31, 2024.
• As a result, 5,913 shares previously reported on April 8, 2022, and 24,078 shares previously reported on December 9, 2022, were not awarded.
• On March 1, 2025, 313 shares were withheld to cover taxes associated with the vesting and settlement of restricted stock units at a price of $7.48 per share.
• Following these transactions, Glessner's beneficially owned securities amount to 114,156 shares.
• The filing was submitted late due to an administrative error, which the company will address in its next proxy statement.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the failure to meet performance targets and the late filing, although the document is primarily factual.

Negatives

• Performance stock units did not vest due to the company not meeting its adjusted EBITDA margin targets.
• The Form 4 filing was submitted late due to an administrative error.

Risks

• Failure to meet performance targets can impact executive compensation and potentially morale.
• Administrative errors in SEC filings can raise concerns about internal controls.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance or financial outlook.

Management Comments

• The Compensation Committee certified the achievement of the 2022-2024 PSUs at a payout factor of 0.00% of target.

Industry Context

Executive compensation is a common area of scrutiny in the biopharmaceutical industry, with performance-based equity awards being a standard component. The failure of PSUs to vest highlights the challenges companies face in achieving financial targets in a competitive and regulated environment.

Comparison to Industry Standards

• Many companies in the biotechnology and pharmaceutical sectors, such as Amgen, Gilead Sciences, and Pfizer, utilize performance-based equity compensation to align executive incentives with shareholder value creation.
• These companies often use metrics like revenue growth, earnings per share (EPS), and clinical trial milestones to determine the vesting of performance-based awards.
• A 0% payout factor for PSUs suggests a significant underperformance relative to the targets set by the Compensation Committee, which could be compared to the performance of similar companies in the sector.

Stakeholder Impact

• Shareholders may be concerned about the company's ability to meet its financial targets, as reflected in the PSU payout.
• Employees may experience lower morale if performance-based compensation is not achieved.

Next Steps

• The company will report all late Form 4s in its next proxy statement.

Key Dates